XML 29 R13.htm IDEA: XBRL DOCUMENT v3.6.0.2

Current Accrued Liabilities and Accrued Research and Development

12 Months Ended

Dec. 31, 2016

Disclosure Component Of Current Accrued Liabilities And Accrued Research And Development [Abstract]

Current Accrued Liabilities and Accrued Research and Development

6. Current Accrued Liabilities and Accrued Research and Development

Current accrued liabilities and accrued research and development consist of the following (in thousands):

	December 31,
	2016				2015
Payroll and related expenses	$	3,753			$	5,866
Legal expenses		275				202
Litigation settlements accrual (Note 7)		4,975				-
Third party research expenses		2,784				5,241
Third party development expenses		2,002				2,072
Return of unused development funding to AstraZeneca (Note 9)		-				7,345
Other accrued liabilities		2,451				1,972
Total	$	16,240			$	22,698

X

- Definition

Disclosure component of current accrued liabilities and accrued research and development.

+ References

No definition available.

+ Details

Name:	dvax_DisclosureComponentOfCurrentAccruedLiabilitiesAndAccruedResearchAndDevelopmentAbstract
Namespace Prefix:	dvax_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.

+ References

No definition available.

+ Details

Name:	us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
Namespace Prefix:	us-gaap_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration